CILP-2 Antibody (B-1): sc-390297

CILP-2 Antibody (B-1) is a mouse monoclonal IgG1 kappa light chain antibody that detects CILP-2 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CILP-2 (B-1) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. The cartilage intermediate layer protein (CILP), which includes CILP-2 isoform, plays a crucial role in the extracellular matrix of cartilaginous tissues, where CILP-2 is predominantly expressed. CILP-2 is particularly important due to involvement in the regulation of chondrocyte function and response to transforming growth factor beta 1 (TGFβ1), which induces CILP-2 expression through the Smad3 signaling pathway. This regulation influences the production of extracellular inorganic pyrophosphate (PPi), a factor that promotes the deposition of calcium pyrophosphate dihydrate crystals, which are associated with various musculoskeletal disorders. The differential expression of CILP and CILP-2 isoforms by chondrocytes highlights their significance in conditions such as osteoarthritis, rheumatoid arthritis, and lumbar disc disease, making anti-CILP-2 antibody (B-1) an essential tool for researchers studying these pathologies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CILP-2 Antibody (B-1) References:

1. One of two chondrocyte-expressed isoforms of cartilage intermediate-layer protein functions as an insulin-like growth factor 1 antagonist.  |  Johnson, K., et al. 2003. Arthritis Rheum. 48: 1302-14. PMID: 12746903
2. Characterisation of cartilage intermediate layer protein (CILP)-induced arthropathy in mice.  |  Yao, Z., et al. 2004. Ann Rheum Dis. 63: 252-8. PMID: 14962958
3. Association study of candidate genes for the prevalence and progression of knee osteoarthritis.  |  Valdes, AM., et al. 2004. Arthritis Rheum. 50: 2497-507. PMID: 15334463
4. The prevalence of autoantibodies against cartilage intermediate layer protein, YKL-39, osteopontin, and cyclic citrullinated peptide in patients with early-stage knee osteoarthritis: evidence of a variety of autoimmune processes.  |  Du, H., et al. 2005. Rheumatol Int. 26: 35-41. PMID: 15378262
5. Altered patterns and synthesis of extracellular matrix macromolecules in early osteoarthritis.  |  Lorenzo, P., et al. 2004. Matrix Biol. 23: 381-91. PMID: 15533759
6. A functional SNP in CILP, encoding cartilage intermediate layer protein, is associated with susceptibility to lumbar disc disease.  |  Seki, S., et al. 2005. Nat Genet. 37: 607-12. PMID: 15864306
7. Transcriptional regulation of the cartilage intermediate layer protein (CILP) gene.  |  Mori, M., et al. 2006. Biochem Biophys Res Commun. 341: 121-7. PMID: 16413503
8. Cartilage intermediate layer protein 2 (CILP-2) is expressed in articular and meniscal cartilage and down-regulated in experimental osteoarthritis.  |  Bernardo, BC., et al. 2011. J Biol Chem. 286: 37758-67. PMID: 21880736
9. CILP-2 is a novel secreted protein and associated with insulin resistance.  |  Wu, T., et al. 2019. J Mol Cell Biol. 11: 1083-1094. PMID: 30896018
10. Association between changes in molecular biomarkers of cartilage matrix turnover and changes in knee articular cartilage: a longitudinal pilot study.  |  Boeth, H., et al. 2019. J Exp Orthop. 6: 19. PMID: 31053993
11. Comparison of Antigen Retrieval Methods for Immunohistochemical Analysis of Cartilage Matrix Glycoproteins Using Cartilage Intermediate Layer Protein 2 (CILP-2) as an Example.  |  Torga, T., et al. 2024. Methods Protoc. 7: PMID: 39311368
12. CILP-2 expression in the intervertebral discs of patients with lumbar radiculopathy.  |  Kõiv, K., et al. 2024. BMC Musculoskelet Disord. 25: 882. PMID: 39506696

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CILP-2 Antibody (B-1) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-CILP-2 Antibody (B-1) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CILP-2 Antibody (B-1) Specifications

Alternate Product Name: CILP-2

Product Clone Name: B-1

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 541-638

Epitope Target: CILP-2

Epitope Species: human

Product Reactivity/Detection: CILP-2

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for CILP-2 Antibody (B-1): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin